All patients
ECOG 0 ECOG 1 Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced UC (mUC) - 2nd Line (L2), atezolizumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMvigor-211 (all population), 2018 0.85 [0.73; 0.99]
IMvigor-211 (PDL1>1%), 2018 0.87 [0.72; 1.06]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.63; 1.21]
0.86 [0.77 ; 0.96 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 3 0% 1,790 moderate not evaluable deaths (OS) (extension)detailed results IMvigor-211 (all population), 2018 0.82 [0.71; 0.94]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.64; 1.18]
0.83 [0.73 ; 0.94 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,165 moderate not evaluable progression or deaths (PFS)detailed results IMvigor-211 (all population), 2018 0.89 [0.60; 1.32]
IMvigor-211 (PDL1>1%), 2018 0.86 [0.53; 1.39]
IMvigor-211 (PDL1>5%), 2018 1.01 [0.76; 1.35]
0.95 [0.77 ; 1.17 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 3 0% 1,790 moderate not evaluable DORdetailed results IMvigor-211 (all population), 2018 0.16 [0.07; 0.35]
IMvigor-211 (PDL1>1%), 2018 0.20 [0.08; 0.50]
IMvigor-211 (PDL1>5%), 2018 0.16 [0.04; 0.55]
0.17 [0.10 ; 0.29 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 3 0% 264 moderate not evaluable objective responses (ORR)detailed results IMvigor-211 (all population), 2018 0.99 [0.68; 1.45]
IMvigor-211 (PDL1>1%), 2018 0.95 [0.61; 1.49]
IMvigor-211 (PDL1>5%), 2018 1.07 [0.58; 2.00]
0.99 [0.76 ; 1.29 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 3 0% 1,790 moderate not evaluable AE (any grade)detailed results IMvigor-211 (all population), 2018 0.38 [0.17; 0.88]
IMvigor-211 (PDL1>5%), 2018 0.67 [0.11; 4.10]
0.42 [0.20 ; 0.90 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable AE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.80 [0.62; 1.04]
IMvigor-211 (PDL1>5%), 2018 1.38 [0.81; 2.33]
1.00 [0.60 ; 1.68 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 69% 1,128 moderate not evaluable AE leading to death (grade 5)detailed results IMvigor-211 (all population), 2018 0.91 [0.46; 1.79]
IMvigor-211 (PDL1>5%), 2018 0.73 [0.16; 3.34]
0.88 [0.47 ; 1.62 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results IMvigor-211 (all population), 2018 0.37 [0.24; 0.57]
IMvigor-211 (PDL1>5%), 2018 0.44 [0.20; 0.99]
0.39 [0.27 ; 0.57 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable SAE (any grade)detailed results IMvigor-211 (all population), 2018 0.92 [0.70; 1.19]
IMvigor-211 (PDL1>5%), 2018 1.79 [1.05; 3.05]
1.23 [0.64 ; 2.37 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 80% 1,128 moderate not evaluable STRAE (any grade)detailed results IMvigor-211 (all population), 2018 0.56 [0.40; 0.78]
IMvigor-211 (PDL1>5%), 2018 0.92 [0.48; 1.80]
0.66 [0.42 ; 1.04 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 41% 1,128 moderate not evaluable TRAE (any grade)detailed results IMvigor-211 (all population), 2018 0.28 [0.19; 0.40]
IMvigor-211 (PDL1>5%), 2018 0.38 [0.19; 0.79]
0.30 [0.21 ; 0.41 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.33 [0.25; 0.45]
IMvigor-211 (PDL1>5%), 2018 0.55 [0.31; 0.99]
0.40 [0.25 ; 0.65 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 57% 1,128 moderate not evaluable TRAE leading to death (grade 5)detailed results IMvigor-211 (all population), 2018 0.42 [0.13; 1.39]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.14; 7.10]
0.53 [0.19 ; 1.46 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results IMvigor-211 (all population), 2018 0.22 [0.12; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.37 [0.15; 0.92]
0.25 [0.15 ; 0.41 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.40 [0.18; 0.89]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.19; 4.97]
0.48 [0.23 ; 0.97 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.42 [0.18; 0.97]
IMvigor-211 (PDL1>5%), 2018 0.49 [0.04; 5.45]
0.43 [0.19 ; 0.94 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Constipation TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.02 [0.00; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.12 [0.01; 2.28]
0.05 [0.01 ; 0.38 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.37 [0.15; 0.88]
IMvigor-211 (PDL1>5%), 2018 2.00 [0.36; 11.15]
0.72 [0.14 ; 3.71 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 66% 1,128 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.04 [0.00; 0.27]
IMvigor-211 (PDL1>5%), 2018 0.09 [0.01; 1.75]
0.05 [0.01 ; 0.26 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.04 [0.01; 0.15]
IMvigor-211 (PDL1>5%), 2018 0.20 [0.04; 0.97]
0.08 [0.01 ; 0.46 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 63% 1,128 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.12 [0.01; 0.95]
IMvigor-211 (PDL1>5%), 2018 0.32 [0.03; 3.14]
0.19 [0.04 ; 0.87 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 05:37 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 290,155,154
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866